Overview

All information and news about Medincell stock (Euronext Paris: MEDCL)

Medincell share price

20.46€

-0.52 / -2.48%

2026-03-19 17:35 (Paris)

Data provided by Euronext, in real time.

See stock quote, chart & historical on Euronext.com

Listed on

Euronext Paris /
B Compartment

ISIN code / Ticker

FR0004065605 /
MEDCL

Number of shares

33,098,886
(September 30, 2025)

Liquidity Provider

Rothschild Martin Maurel

Analyst coverage

Medincell is followed by the analysts listed. Please note that any opinions, estimates, or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Medincell or its management. Medincell does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions, or recommendations.

Company

Analyst

Contact

Evercore

Michael DiFiore

Truist Securities

Les Sulewski

H.C. Wainwright & Co.

Raghuram Selvaraju

Jefferies

Shan Hama

Stifel

Oscar Haffen Lamm

ODDO BHF

Martial Descoutures

Kepler Chevreux

Nicolas Pauillac

Portzamparc

Mohamed Kaabouni

TP ICAP

Jean-Pierre Tabart

Documentation

February 2026

Corporate presentation

2025

CSR report

Latest news

Medincell announces successful c. €48 million Private Placement
March 6, 2026

Medincell announces successful c. €48 million Private Placement

Medincell launches a private placement for international institutional investors
March 5, 2026

Medincell launches a private placement for international institutional investors

Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026
March 4, 2026

Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026

Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
February 24, 2026

Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
February 20, 2026

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults

Investors contacts

Medincell

David Heuzé

Head of Corporate and Financial Communications, and ESG

Medincell

Grace Kim

Head of US Financial Strategy & IR

Investor relations

Louis-Victor Delouvrier
& Alban Dufumier

Newcap

Media

Nicolas Merigeau

Newcap